Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
Front Immunol ; 12: 783725, 2021.
Article in English | MEDLINE | ID: covidwho-1554650

ABSTRACT

Interferons (IFNs) are cytokines that possess antiviral, antiproliferative, and immunomodulatory actions. IFN-α and IFN-ß are two major family members of type-I IFNs and are used to treat diseases, including hepatitis and multiple sclerosis. Emerging evidence suggests that type-I IFN receptors (IFNARs) are also expressed by microglia, astrocytes, and neurons in the central and peripheral nervous systems. Apart from canonical transcriptional regulations, IFN-α and IFN-ß can rapidly suppress neuronal activity and synaptic transmission via non-genomic regulation, leading to potent analgesia. IFN-γ is the only member of the type-II IFN family and induces central sensitization and microglia activation in persistent pain. We discuss how type-I and type-II IFNs regulate pain and infection via neuro-immune modulations, with special focus on neuroinflammation and neuro-glial interactions. We also highlight distinct roles of type-I IFNs in the peripheral and central nervous system. Insights into IFN signaling in nociceptors and their distinct actions in physiological vs. pathological and acute vs. chronic conditions will improve our treatments of pain after surgeries, traumas, and infections.


Subject(s)
Acute Pain/immunology , Chronic Pain/immunology , Interferon Type I/metabolism , Interferon-gamma/metabolism , Neuroinflammatory Diseases/immunology , Acute Pain/pathology , Animals , Chronic Pain/pathology , Disease Models, Animal , Humans , Neuroglia/cytology , Neuroglia/immunology , Neuroglia/pathology , Neuroinflammatory Diseases/pathology , Nociceptors/immunology , Nociceptors/metabolism , Receptors, Interferon/metabolism , Signal Transduction/immunology , Spinal Cord/cytology , Spinal Cord/immunology , Spinal Cord/pathology
3.
Front Immunol ; 12: 747143, 2021.
Article in English | MEDLINE | ID: covidwho-1497080

ABSTRACT

Regulatory T cells (Tregs) are the major determinant of peripheral immune tolerance. Many Treg subsets have been described, however thymus-derived and peripherally induced Tregs remain the most important subpopulations. In multiple sclerosis, a prototypical autoimmune disorder of the central nervous system, Treg dysfunction is a pathogenic hallmark. In contrast, induction of Treg proliferation and enhancement of their function are central immune evasion mechanisms of infectious pathogens. In accordance, Treg expansion is compartmentalized to tissues with high viral replication and prolonged in chronic infections. In friend retrovirus infection, Treg expansion is mainly based on excessive interleukin-2 production by infected effector T cells. Moreover, pathogens seem also to enhance Treg functions as shown in human immunodeficiency virus infection, where Tregs express higher levels of effector molecules such as cytotoxic T-lymphocyte-associated protein 4, CD39 and cAMP and show increased suppressive capacity. Thus, insights into the molecular mechanisms by which intracellular pathogens alter Treg functions might aid to find new therapeutic approaches to target central nervous system autoimmunity. In this review, we summarize the current knowledge of the role of pathogens for Treg function in the context of autoimmune neuroinflammation. We discuss the mechanistic implications for future therapies and provide an outlook for new research directions.


Subject(s)
Autoimmune Diseases/immunology , Autoimmune Diseases/microbiology , Neuroinflammatory Diseases/immunology , Neuroinflammatory Diseases/microbiology , T-Lymphocytes, Regulatory/immunology , Animals , Humans , Persistent Infection/immunology
SELECTION OF CITATIONS
SEARCH DETAIL